-+ 0.00%
-+ 0.00%
-+ 0.00%

Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum

Barchart·01/06/2026 08:30:00
Listen to the news

BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today announced dosing of the first patient in the Phase Ib clinical trial of BBT002, a novel platform-in-a-molecule bispecific antibody targeting IL-4Rα and IL-5, in patients with chronic obstructive pulmonary disease (COPD). The Phase Ib study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BBT002 in COPD as well as other type 2 inflammatory respiratory indications, including asthma and chronic rhinosinusitis with nasal polyps. Initial data are anticipated in the second half of 2026.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.